DAWN Q3 2024 Earnings — Day One Biopharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

DAWNDay One Biopharmaceuticals, Inc.

$2B

Q3 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$94M

Gross Profit

$92M98.3% margin

Operating Income

$30M31.6% margin

Net Income

$37M39.5% margin

EPS (Diluted)

$0.38

QoQ Revenue Growth

+1044.5%

Cash Flow

Operating Cash Flow

$51M

Free Cash Flow

-$5M

Stock-Based Comp.

$12M

Balance Sheet

Total Assets

$601M

Total Liabilities

$45M

Stockholders' Equity

$555M

Cash & Equivalents

$423M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$94M	$0	—
Gross Profit	$92M	-$99,000	+93202.0%
Operating Income	$30M	-$51M	+157.6%
Net Income	$37M	-$46M	+180.3%

Revenue Segments

License

$74M79%

Product

$20M21%